News Digest / Ticker: JSPR

Ticker: JSPR

04:00am, Tuesday, Jul 08, 2025

Jasper Therapeutics Plummets 43.7% on Drug Lot Issues: A Cautionary Tale for Biotech Investors

Jasper Therapeutics (NASDAQ: JSPR) shares plummeted 43.7% in premarket trading due to issues with a drug lot affecting its clinical study on briquilimab. The company is investigating the manufacturing problems, halting its ETESIAN asthma study, and implementing cost-cutting measures.